DNA methylation represses IFN-γ-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells

Molecular Cancer Research

Volumn 6, Issue 12, 2008, Pages 1841-1851

  McGough, Jon M ^a   Yang, Dafeng ^a   Huang, Shuang ^a   Georgi, David ^a   Hewitt, Stephen M ^b   Röcken, Christoph ^c   Tänzer, Marc ^d   Ebert, Matthias P A ^d   Liu, Kebin ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE 3B; GENOMIC DNA; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; METHYL CPG BINDING PROTEIN; PROTEIN INHIBITOR OF ACTIVATED STAT; RECOMBINANT GAMMA INTERFERON; STAT1 PROTEIN;

ARTICLE; BINDING KINETICS; CHROMATIN IMMUNOPRECIPITATION; COLON CARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DNA METHYLATION; DNA SEQUENCE; ELECTROPHORESIS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSCRIPTION INITIATION; TUMOR CELL;

COLONIC NEOPLASMS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; INTERFERON REGULATORY FACTORS; INTERFERON-GAMMA; PHENOTYPE; PROMOTER REGIONS, GENETIC; STAT1 TRANSCRIPTION FACTOR;

EID: 57749097557     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-08-0280     Document Type: Article

References (51)

1. Contursi C, Wang IM, Gabriele L, et al. IFN consensus sequence binding protein potentiates STAT1-dependent activation of IFNγ-responsive promoters in macrophages. Proc Natl Acad Sci U S A 2000;97:91-6.
2. Holtschke T, Lohler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 1996;87:307-17.
3. Yang D, Thangaraju M, Greeneltch K, et al. Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. Cancer Res 2007;67:3301-9.
4. Greeneltch KM, Schneider M, Steinberg SM, et al. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms. Cancer Res 2007;67:10406-16.
5. Gabriele L, Phung J, Fukumoto J, et al. Regulation of apoptosis in myeloid cells by interferon consensus sequence-binding protein. J Exp Med 1999;190:411-21.
6. Middleton MK, Zukas AM, Rubinstein T, et al. Identification of 12/15-lipoxygenase as a suppressor of myeloproliferative disease. J Exp Med 2006;203:2529-40.
7. Schmidt M, Nagel S, Proba J, et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukemias. Blood 1998;91:22-9.
8. Liu K, Abrams SI. Coordinate regulation of IFN consensus sequence-binding protein and caspase-1 in the sensitization of human colon carcinoma cells to Fas-mediated apoptosis by IFN-γ. J Immunol 2003;170:6329-37.
9. Yang D, Thangaraju M, Browning DD, et al. IFN regulatory factor 8 mediates apoptosis in nonhemopoietic tumor cells via regulation of Fas expression. J Immunol 2007;179:4775-82.
10. Egwuagu CE, Li W, Yu CR, et al. Interferon-γ induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors. Oncogene 2006;25:3670-9.
11. Lee KY, Geng H, Ng KM, et al. Epigenetic disruption of interferon-γ response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. Oncogene 2008;27:5267-76.
12. Kanno Y, Levi BZ, Tamura T, Ozato K. Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res 2005;25:770-9.
13. Kanno Y, Kozak CA, Schindler C, et al. The genomic structure of the murine ICSBP gene reveals the presence of the γ interferon-responsive element, to which an ISGF3 α subunit (or similar) molecule binds. Mol Cell Biol 1993;13:3951-63.
14. Valente G, Ozmen L, Novelli F, et al. Distribution of interferon-γ receptor in human tissues. Eur J Immunol 1992;22:2403-12.
15. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264:1415-21.
16. Ihle JN. STATs: signal transducers and activators of transcription. Cell 1996;84:331-4.
17. Bach EA, Aguet M, Schreiber RD. The IFN γ receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91.
18. Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997;17:121-34.
19. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416:552-6.
20. Brattain MG, Fine WD, Khaled FM, Thompson J, Brattain DE. Heterogeneity of malignant cells from a human colonic carcinoma. Cancer Res 1981;41:1751-6.
21. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-93.
22. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006;6:107-16.
23. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
24. Dawson DW, Hong JS, Shen RR, et al. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene 2007;26:4243-52.
25. Nelson WG, Yegnasubramanian S, Agoston AT, et al. Abnormal DNA methylation, epigenetics, and prostate cancer. Front Biosci 2007;12:4254-66.
26. Leu YW, Yan PS, Fan M, et al. Loss of estrogen receptor signaling triggers epigenetic silencing of downstream targets in breast cancer. Cancer Res 2004;64:8184-92.
27. Kerr KM, Galler JS, Hagen JA, Laird PW, Laird-Offringa IA. The role of DNA methylation in the development and progression of lung adenocarcinoma. Dis Markers 2007;23:5-30.
28. Bird AP, Wolffe AP. Methylation-induced repression - belts, braces, and chromatin. Cell 1999;99:451-4.
29. Liu B, Liao J, Rao X, et al. Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 1998;95:10626-31.
30. Liu B, Mink S, Wong KA, et al. PIAS1 selectively inhibits interferon-inducible genes and is important in innate immunity. Nat Immunol 2004;5:891-8.
31. Rogers RS, Horvath CM, Matunis MJ. SUMO modification of STAT1and its role in PIAS-mediated inhibition of gene activation. J Biol Chem 2003;278:30091-7.
32. Lyst MJ, Nan X, Stancheva I. Regulation of MBD1-mediated transcriptional repression by SUMO and PIAS proteins. EMBO J 2006;25:5317-28.
33. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003;3:253-66.
34. Petak I, Danam RP, Tillman DM, et al. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ 2003;10:211-7.
35. Chen J, Rocken C, Lofton-Day C, et al. Molecular analysis of APC promoter methylation and protein expression in colorectal cancer metastasis. Carcinogenesis 2005;26:37-43.
36. Ebert MP, Model F, Mooney S, et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology 2006;131:1418-30.
37. Kim TY, Zhong S, Fields CR, Kim JH, Robertson KD. Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma. Cancer Res 2006;66:7490-501.
38. Chan MW, Wei SH, Wen P, et al. Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 2005;11:7376-83.
39. Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem 2005;74:481-514.
40. Liu K, McDuffie E, Abrams SI. Exposure of human primary colon carcinoma cells to anti-Fas interactions influences the emergence of pre-existing Fas-resistant metastatic subpopulations. J Immunol 2003;171:4164-74.
41. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad O. Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 2004;40:1593-8.
42. Cespedes MV, Espina C, Garcia-Cabezas MA, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007;170:1077-85.
43. Boyd D, Florent G, Kim P, Brattain M. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res 1988;48:3112-6.
44. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993;3:226-31.
45. Boyes J, Bird A. DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. Cell 1991;64:1123-34.
46. Murray EJ, Grosveld F. Site specific demethylation in the promoter of human γ-globin gene does not alleviate methylation mediated suppression. EMBO J 1987;6:2329-35.
47. Fatemi M, Wade PA. MBD family proteins: reading the epigenetic code. J Cell Sci 2006;119:3033-7.
48. Yang D, Stewart TJ, Smith KK, Georgi D, Abrams SI, Liu K. Downregulation of IFN-γR in association with loss of Fas function is linked to tumor progression. Int J Cancer 2008;122:350-62.
49. Yang D, Ud Din N, Browning DD, Abrams SI, Liu K. Targeting lymphotoxin h receptor with tumor-specific T lymphocytes for tumor regression. Clin Cancer Res 2007;13:5202-10.
50. + memory T cells. Proc Natl Acad Sci U S A 2002;99:6192-7.
51. Andrews NC, Faller DV. A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 1991;19:2499.